These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34546618)

  • 1. Frequency of anxiety and depression and screening performance of the Edmonton Symptom Assessment Scale in a psycho-oncology clinic.
    Valentine A; Brown J; Lacourt T; Chen M; De La Garza R; Bruera E
    Psychooncology; 2022 Feb; 31(2):290-297. PubMed ID: 34546618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression.
    Bagha SM; Macedo A; Jacks LM; Lo C; Zimmermann C; Rodin G; Li M
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):60-9. PubMed ID: 22694595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Proportion of Patients With Musculoskeletal Sarcomas Demostrate Symptoms of Depression or Anxiety?
    Polfer EM; Alici Y; Baser RE; Healey JH; Bartelstein MK
    Clin Orthop Relat Res; 2022 Nov; 480(11):2148-2160. PubMed ID: 35901433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Edmonton Symptom Assessment System (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up.
    Ripamonti CI; Bandieri E; Pessi MA; Maruelli A; Buonaccorso L; Miccinesi G
    Support Care Cancer; 2014 Mar; 22(3):783-93. PubMed ID: 24276952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for symptoms of anxiety and depression in patients treated with renal replacement therapy: utility of the Edmonton Symptom Assessment System-Revised.
    Tang E; Dano S; Edwards N; Macanovic S; Ford H; Bartlett S; Howell D; Li M; Novak M; Mucsi I
    Qual Life Res; 2022 Feb; 31(2):597-605. PubMed ID: 34138450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining brief and ultra-brief anxiety and depression screening methods in a real-world epilepsy clinic sample.
    Munger Clary HM; Wan M; Conner K; Brenes GA; Kimball J; Kim E; Duncan P; Snively BM
    Epilepsy Behav; 2021 May; 118():107943. PubMed ID: 33839449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of depression among oncology outpatients and association with other symptoms.
    Rhondali W; Perceau E; Berthiller J; Saltel P; Trillet-Lenoir V; Tredan O; Coulon JP; Bruera E; Filbet M
    Support Care Cancer; 2012 Nov; 20(11):2795-802. PubMed ID: 22350596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the optimal cutoff values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in irritable bowel syndrome.
    Snijkers JTW; van den Oever W; Weerts ZZRM; Vork L; Mujagic Z; Leue C; Hesselink MAM; Kruimel JW; Muris JWM; Bogie RMM; Masclee AAM; Jonkers DMAE; Keszthelyi D
    Neurogastroenterol Motil; 2021 Dec; 33(12):e14161. PubMed ID: 33938601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing Cutoff Points for Defining Symptom Severity Using the Edmonton Symptom Assessment System-Revised Japanese Version.
    Yamaguchi T; Morita T; Nitto A; Takahashi N; Miyamoto S; Nishie H; Matsuoka J; Sakurai H; Ishihara T; Tarumi Y; Ogawa A
    J Pain Symptom Manage; 2016 Feb; 51(2):292-7. PubMed ID: 26598039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between malnutrition risk and revised Edmonton Symptom Assessment System (ESAS-r) scores in an adult outpatient oncology population: a cross-sectional study.
    McLay K; Stonewall N; Forbes L; Peters C
    J Patient Rep Outcomes; 2024 Jul; 8(1):71. PubMed ID: 38995461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Edmonton Symptom Assessment System as a screening tool for depression and anxiety.
    Vignaroli E; Pace EA; Willey J; Palmer JL; Zhang T; Bruera E
    J Palliat Med; 2006 Apr; 9(2):296-303. PubMed ID: 16629559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening male prisoners for depression and anxiety with the PHQ-9 and GAD-7 at NHS Healthcheck: patterns of symptoms and caseness threshold.
    Butcher E; Packham C; Williams M; Miksza J; Kaul A; Khunti K; Morriss R
    BMC Psychiatry; 2021 Sep; 21(1):446. PubMed ID: 34496806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe.
    Chibanda D; Verhey R; Gibson LJ; Munetsi E; Machando D; Rusakaniko S; Munjoma R; Araya R; Weiss HA; Abas M
    J Affect Disord; 2016 Jul; 198():50-5. PubMed ID: 27011359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer.
    Salvo N; Zeng L; Zhang L; Leung M; Khan L; Presutti R; Nguyen J; Holden L; Culleton S; Chow E
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):139-48. PubMed ID: 21652191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity and specificity of the Patient Health Questionnaire (PHQ-9, PHQ-8, PHQ-2) and General Anxiety Disorder scale (GAD-7, GAD-2) for depression and anxiety diagnosis: a cross-sectional study in a Peruvian hospital population.
    Villarreal-Zegarra D; Barrera-Begazo J; Otazú-Alfaro S; Mayo-Puchoc N; Bazo-Alvarez JC; Huarcaya-Victoria J
    BMJ Open; 2023 Sep; 13(9):e076193. PubMed ID: 37714674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4).
    Renovanz M; Soebianto S; Tsakmaklis H; Keric N; Nadji-Ohl M; Beutel M; Ringel F; Wollschläger D; Hickmann AK
    Support Care Cancer; 2019 Dec; 27(12):4469-4477. PubMed ID: 30904948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncology Nurses' Attitudes Toward the Edmonton Symptom Assessment System: Results From a Large Cancer Care Ontario Study.
    Green E; Yuen D; Chasen M; Amernic H; Shabestari O; Brundage M; Krzyzanowska MK; Klinger C; Ismail Z; Pereira J
    Oncol Nurs Forum; 2017 Jan; 44(1):116-125. PubMed ID: 27991609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the best cut-off points of PHQ-2 and GAD-2 for detecting depression and anxiety in Italian cardiovascular inpatients.
    Giuliani M; Gorini A; Barbieri S; Veglia F; Tremoli E
    Psychol Health; 2021 Sep; 36(9):1088-1101. PubMed ID: 33026888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Accuracy of the Edmonton Symptom Assessment System for the Assessment of Depression in Patients With Cancer: A Systematic Review and Meta-Analysis.
    Boonyathee S; Nagaviroj K; Anothaisintawee T
    Am J Hosp Palliat Care; 2018 Apr; 35(4):731-739. PubMed ID: 29186983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability and Repeatability of the Distress Thermometer (DT) and the Edmonton Symptom Assessment System-Revised (ESAS-r) with Parents of Childhood Cancer Survivors.
    Leclair T; Carret AS; Samson Y; Sultan S
    PLoS One; 2016; 11(7):e0159773. PubMed ID: 27454432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.